Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)

NCT06577441 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

54

Enrollment

NIH

Sponsor class

Conditions

Myelodysplastic Syndrome

Interventions

PROCEDURE: Biospecimen Collection
PROCEDURE: Bone Marrow Aspiration
PROCEDURE: Bone Marrow Biopsy
DRUG: Decitabine and Cedazuridine
DRUG: Enasidenib

Sponsor

National Cancer Institute (NCI)